NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity. - Wikidata - awgldk - TriplyDB

NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity.

NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity.

http://www.wikidata.org/entity/Q38412095

about

Administration d'anti-inflammatoires non stéroïdiens aux enfants ayant des antécédents de sibilance Risk of asthma exacerbation associated with nonsteroidal anti-inflammatory drugs in childhood asthma: A nationwide population-based cohort study in Taiwan.Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis.Practical Management of Patients with a History of Immediate Hypersensitivity to Common non-Beta-Lactam Drugs.Bioactive food chemicals and gastrointestinal symptoms: a focus of salicylates.Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis.Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease.Comorbidities in adults with asthma: Population-based cross-sectional analysis of 1.4 million adults in Scotland.Nonsteroidal anti-inflammatory drug administration in children with history of wheeze.Precision Medicine in Chronic Rhinosinusitis with Nasal Polyps.

P2860

Q26741573-FE99F5FD-1261-4E75-A7DA-26292A21B0D6 Q37354816-E1529627-1881-4ACF-B0B3-30B82DEEC402 Q38609538-31962462-0E5C-4FFF-8946-B2CDF652382D Q38682358-44E8BC21-2681-4A0E-940B-DA7B5EEC27FC Q38937576-72EF75A2-0D1A-4F6A-8A5D-4D8362012201 Q38973949-56074EFC-8F84-4A03-8C64-1415D9DC7AAD Q39175214-0D11080D-1C01-45F5-843E-D8EBA690338E Q40139808-6C580F54-868A-4209-AE18-15710CBF0891 Q40623616-6B6C2980-0BFF-4998-99C2-8EE695103821 Q55097573-D72CD6F2-2510-4115-A3E8-B9BEA78E3853

P2860

NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity.

http://www.wikidata.org/entity/Q38412095

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

NSAID-exacerbated respiratory ...... nd increased asthma morbidity.

@en

type

label

NSAID-exacerbated respiratory ...... nd increased asthma morbidity.

@en

prefLabel

NSAID-exacerbated respiratory ...... nd increased asthma morbidity.

@en

P1433

Q38412095-7FF82610-0518-4093-9417-4453DE390B7F

P1476

Q38412095-D35BC9B1-E63F-4E27-A461-C2C867B9AE65

P2093

Q38412095-69752210-CE97-4788-AF95-41233E021C14

Q38412095-704CD3B8-EFC6-4B35-BA14-F79E7E1BD392

Q38412095-9DBED429-5745-431B-926E-957063724B02

Q38412095-BFC0CAF8-FF65-4690-B223-78DA9566A690

Q38412095-D44A015C-37FA-4174-BEDA-950F9C184F51

P2860

Q38412095-02088DA1-7127-47BA-9CD8-B68F576FC2AF

Q38412095-0A225AAB-46B0-474C-AE3E-3A41813A663D

Q38412095-16E605B5-BC0E-4C47-B8A0-B74B945B77F2

Q38412095-23077E48-5F08-4A50-BE14-34A26955E41F

Q38412095-31579B36-4A17-4AC7-909D-E9E764137348

Q38412095-3395CC09-A533-4B8F-81CE-D5B88D37181D

Q38412095-3D031ADB-0B86-4B57-A975-05F61E0C2E54

Q38412095-3D54544C-64CE-433C-8997-F90094479EC0

Q38412095-4291478E-9C7C-4D55-A2F4-AA04EC557ECB

Q38412095-526001BB-F525-4913-B398-5AE7CD8421A3

P304

Q38412095-55641703-CF0E-43C8-8F6B-0A6FCC2DCB4C

P31

Q38412095-6D089572-0F0B-41BE-8CD4-5F822B941093

Q38412095-fc46ccc9-cd34-4fb2-adef-7339e47f47b2

P356

Q38412095-6946E5F4-A7A1-4C69-A99D-7FCF198F3F05

P433

Q38412095-0BB71122-8331-4E23-B47D-EE216EA23A2C

P478

Q38412095-07D7ADC5-F597-4469-B140-71E4BC300575

P50

Q38412095-73B126B2-F3C4-4F01-8A6A-CA9B73091FD5

P577

Q38412095-7670C49F-7F17-4E1A-81AD-78E3C745B27F

P5875

Q38412095-586F2F34-F712-4108-9FEB-B54646F73924

P698

Q38412095-D26DFBE2-65DC-4010-A86E-027E92937D0E

P356

P1433

P1476

NSAID-exacerbated respiratory ...... nd increased asthma morbidity.

@en

P2093

B J Lipworth

http://www.w3.org/2001/XMLSchema#string

C Jackson

http://www.w3.org/2001/XMLSchema#string

D R Morales

http://www.w3.org/2001/XMLSchema#string

P T Donnan

http://www.w3.org/2001/XMLSchema#string

V H Santiago

http://www.w3.org/2001/XMLSchema#string

P2860

Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice

Estimating the mean and variance from the median, range, and the size of a sample

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland

Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease

Safety of a specific COX-2 inhibitor in aspirin-induced asthma

Improvements in an oral aspirin challenge protocol for the diagnosis of aspirin hypersensitivity

Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma

Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma

The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients

P304

828-835

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/ALL.12629

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274726546

http://www.w3.org/2001/XMLSchema#string

P698

25855099

http://www.w3.org/2001/XMLSchema#string